How is this drug different from existing injections?

This drug is an oral pill instead of an injection, offering greater convenience for patients.

When will the drug be available?

Merck has not announced a launch date yet, but distribution is expected to begin in the coming months.

Merck Gets First Approval for Oral PCSK9 Pill to Lower LDL

Merck (MRK) received the first-ever regulatory approval for an oral PCSK9 pill to lower LDL cholesterol, initiating a new rivalry with existing injectable treatments from Amgen and Regeneron.

July 16, 2026

2 min read

Source: Investor's Business Daily

Merck (MRK) has secured the first-ever approval for an oral PCSK9 pill to lower LDL cholesterol, the company announced today. This milestone opens a new market for oral therapy as an alternative to current injections.

The Product

The new drug is an oral pill targeting the PCSK9 protein, the same target as injectable drugs from Amgen (AMGN) and Regeneron (REGN). It is the first oral treatment in this class, offering patients a more convenient option compared to injections.

Pricing and Availability

Merck has not yet announced the drug's price or launch date. The company is expected to set pricing in the coming weeks as distribution begins.

Competition

Merck faces competition from existing PCSK9 injectables like Amgen's Repatha and Regeneron's Praluent, which are widely used for cholesterol reduction. The oral pill may attract patients who prefer to avoid injections, potentially expanding the overall market.

Potential Impact on the Company

This approval represents a significant growth opportunity for Merck in the cardiovascular drug market, valued at over $10 billion annually. The drug could boost Merck's revenue and reduce its reliance on current cancer drugs.

Frequently Asked Questions

A PCSK9 drug inhibits a protein that raises LDL cholesterol, thereby lowering cholesterol levels.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.